An2 Therapeutics Closed $80 Million Series B Financing To Advance Novel Nontuberculous Mycobacterial Lung Disease Program
An2 Therapeutics Closed $80 Million Series B Financing To Advance Novel Nontuberculous Mycobacterial Lung Disease Program
01/07/22, 7:00 AM
Location
menlo parkMoney raised
$80 million
Industry
biotechnology
science and engineering
health care
Round Type
series b
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today announced several significant strides in the company's development over the past year.
Company Info
Location
menlo park, california, united states
Additional Info
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. AN2 is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM). For more information, visit www.an2therapeutics.com.
SOURCE AN2 Therapeutics, Inc.